Abstract
SOX2 is a transcription factor related to the maintenance of stem cells in a pluripotent state. Podoplanin is a type of transmembrane sialoglycoprotein, which plays an important role in tumor progression and metastasis. This study aims to determine association of SOX2 and podoplanin expression in the progression of oral squamous cell carcinomas and to elucidate the association between two proteins. Label="METHODOLOGY">The immunohistochemical expression of SOX2 and podoplanin were evaluated in 60 cases of primary oral squamous cell carcinomas. The correlation between the SOX2 and podoplanin expression and the clinicopathological features of the tumors and the patient outcomes were assessed. RESULTS The expression of SOX2 was seen in 38/60 (63%) of the cases and the expression for podoplanin was seen in 45/60 (75%) cases. There was a significant inverse correlation between the expression of SOX2 and podoplanin with the tumor grade (p=0.002 and p=0.017, respectively). There was a high expression of SOX2 in 9/13 cases that presented with disease free survival. Survival analysis showed that a high expression of SOX2 correlated positively (p=0.043) with the disease-free survival. There was a significant positive association between the pattern of SOX2 and podoplanin expression (p=0.002). CONCLUSION A high expression of SOX2 was associated with better disease-free survival. The expression of podoplanin was associated with the degree of differentiation of the tumors. Analysis of these biomarkers can aid in the prognosis and treatment of oral squamous cell carcinomas.
Highlights
Oral squamous cell carcinoma is the sixth most common cancer reported globally
A study evaluating the expression of SOX2 in oral squamous cell carcinomas has shown that a tumor with a high nuclear expression of SOX2 had longer disease-free survival period following postoperative radiotherapy.[5]
The material for the study comprised of archival formalin fixed paraffin embedded tumor blocks (FFPE) of primary oral squamous cell carcinoma cases (n=60)
Summary
Oral squamous cell carcinoma is the sixth most common cancer reported globally. The annual incidence of oral squamous cell carcinomas is over 300,000 cases, of which 62% arise in developing countries.[1] Though diagnostic techniques have improved, the survival rates are poor and have remained more or less the same for years, with a 5-year survival rate of approximately 50% cases from the time of diagnosis.[2] there is a need to understand the proliferative activity, degree of differentiation, and the invasion and metastatic potential of the tumor.[3]. The role of SOX2 in oral squamous cell carcinoma is not widely explored and is still not precisely understood. A study evaluating the expression of SOX2 in oral squamous cell carcinomas has shown that a tumor with a high nuclear expression of SOX2 had longer disease-free survival period following postoperative radiotherapy.[5]. It has been shown that SOX2 was able to protect malignant cells from apoptosis throughout the journey of carcinogenesis.[6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
